Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixabepilone Prior to Surgery for High-risk Localized Prostate Cancer
NCT00672009Phase 2Terminated
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Apr 2008
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixabepilone in prostate cancer (PCa), sponsored by Cedars-Sinai Medical Center. Primary endpoint: Biochemical Response Rate. Started Apr 2008; status: terminated.
02
Drugs
ixabepilone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00672009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00672009.